- Home
- CAC vs PHAR Comparison
CAC vs PHAR Comparison
Compare CAC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAC
- PHAR
- Stock Information
- Founded
- CAC 1875
- PHAR 1988
- Country
- CAC United States
- PHAR Netherlands
- Employees
- CAC N/A
- PHAR N/A
- Industry
- CAC Major Banks
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- CAC Finance
- PHAR Health Care
- Exchange
- CAC Nasdaq
- PHAR Nasdaq
- Market Cap
- CAC 688.3M
- PHAR 951.7M
- IPO Year
- CAC 1997
- PHAR N/A
- Fundamental
- Price
- CAC $41.03
- PHAR $14.44
- Analyst Decision
- CAC Buy
- PHAR Strong Buy
- Analyst Count
- CAC 3
- PHAR 3
- Target Price
- CAC $48.00
- PHAR $30.00
- AVG Volume (30 Days)
- CAC 56.5K
- PHAR 12.7K
- Earning Date
- CAC 10-28-2025
- PHAR 10-23-2025
- Dividend Yield
- CAC 4.22%
- PHAR N/A
- EPS Growth
- CAC 4.80
- PHAR N/A
- EPS
- CAC 3.11
- PHAR N/A
- Revenue
- CAC $197,501,000.00
- PHAR $339,836,000.00
- Revenue This Year
- CAC $42.11
- PHAR $16.63
- Revenue Next Year
- CAC $5.51
- PHAR $6.77
- P/E Ratio
- CAC $12.78
- PHAR N/A
- Revenue Growth
- CAC 21.74
- PHAR 22.44
- 52 Week Low
- CAC $34.53
- PHAR $7.31
- 52 Week High
- CAC $50.07
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- CAC 56.74
- PHAR 54.40
- Support Level
- CAC $39.50
- PHAR $13.63
- Resistance Level
- CAC $40.75
- PHAR $15.27
- Average True Range (ATR)
- CAC 0.87
- PHAR 0.97
- MACD
- CAC -0.03
- PHAR -0.14
- Stochastic Oscillator
- CAC 70.36
- PHAR 37.01
About CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.